| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | PL-DI | CTRPv2 | pan-cancer | AAC | -0.0053 | 0.9 |
| mRNA | Erlotinib | FIMM | pan-cancer | AAC | -0.031 | 0.9 |
| mRNA | BMS-195614 | CTRPv2 | pan-cancer | AAC | -0.0064 | 0.9 |
| mRNA | Panobinostat | FIMM | pan-cancer | AAC | -0.021 | 0.9 |
| mRNA | Erlotinib | CCLE | pan-cancer | AAC | -0.0075 | 0.9 |
| mRNA | lapatinib | CTRPv2 | pan-cancer | AAC | 0.0059 | 0.9 |
| mRNA | cediranib | CTRPv2 | pan-cancer | AAC | -0.0089 | 0.9 |
| mRNA | HC-067047 | CTRPv2 | pan-cancer | AAC | -0.0061 | 0.9 |
| mRNA | BRD-K29086754 | CTRPv2 | pan-cancer | AAC | -0.012 | 0.9 |
| mRNA | WZ3105 | GDSC1000 | pan-cancer | AAC | -0.0048 | 0.9 |